ANRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ANRO is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is near short-term support but the technicals are still weak, no fresh bullish proprietary signal is present, hedge funds are selling, and the most recent analyst action is mixed despite a few positive long-term views. I would not call this an immediate buy given the investor wants to act now rather than wait for a better setup.
Price closed at 19.80, down 1.08% on the day and slightly below the S1 support area of 20.14, with S2 at 19.17 nearby. MACD histogram is -0.375 and still below zero, which keeps momentum bearish, though the negative reading is contracting. RSI_6 at 25.23 suggests the stock is very weak and near oversold territory, but not yet showing a clear reversal. Moving averages are converging, which usually signals a possible inflection point, but not confirmed strength yet. Overall trend is still fragile and below the pivot of 21.71.
BofA initiated coverage with a Buy rating and $35 target, and H.C. Wainwright keeps a Buy rating with a $50 target, showing continued belief in the long-term pipeline. The company also has a cash runway supported by prior financing, which helps fund upcoming studies.
The biggest recent negative is that ALTO-101 failed its Phase 2 primary endpoints in schizophrenia-related cognitive impairment, and some analysts removed it from estimates. Hedge funds are selling aggressively, with selling up 159.20% over the last quarter. Insider trading is neutral with no meaningful buying support. The stock has no recent news catalysts, and the market appears to be waiting on later-stage depression pipeline execution rather than rewarding current results.
No usable latest-quarter financial snapshot was provided, so there is no reliable revenue or earnings trend to assess. The most relevant financial detail available is balance-sheet related: the company completed a $120M private placement in Q4 and was said to have about $275M in cash, with runway extended through 2029. For a clinical-stage biotech like ANRO, this is the key financial strength, but there is no evidence yet of commercial revenue growth or operating profitability.
Analyst sentiment is split but still moderately constructive on the long-term story. Baird lowered its target to $36 from $38 while keeping Outperform. Wedbush raised its target to $24 from $21 but kept Neutral, reflecting caution after ALTO-101. BofA initiated with a Buy and $35 target, which is a notable positive. H.C. Wainwright remains bullish with Buy and $50 target, while JonesResearch also kept a Buy and called the pullback an attractive entry point. Overall, Wall Street pros are constructive on the pipeline but divided on near-term execution, with the cons side focused on the failed ALTO-101 readout and the pros side focused on ALTO-207 and the broader depression pipeline.
